Dr. Hofmeister Discusses Sequencing Treatment in Myeloma

Craig Hofmeister, MD
Published: Tuesday, Oct 31, 2017



Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.

General upfront treatment for myeloma is a proteasome inhibitor, immunomodulatory drug (IMiD), dexamethasone, and then transplant. From there, based on the patient’s risk profile, it is a 1- to 3-drug maintenance regimen.

At the time of relapse, monoclonal antibodies are showing excellent response rates in combination. As for the third- and fourth-line settings, agents are currently being tested but are showing significant side effects, says Hofmeister.
 


Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.

General upfront treatment for myeloma is a proteasome inhibitor, immunomodulatory drug (IMiD), dexamethasone, and then transplant. From there, based on the patient’s risk profile, it is a 1- to 3-drug maintenance regimen.

At the time of relapse, monoclonal antibodies are showing excellent response rates in combination. As for the third- and fourth-line settings, agents are currently being tested but are showing significant side effects, says Hofmeister.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x